Celator Publishes Pre-Clinical Data For Lukemia Drug CPX-351

(RTTNews) - Oncology drugmaker Celator Pharmaceuticals, Inc. (CPXX) Monday said its compound CPX-351 showed "potent" anti-leukemic activity in children with acute lymphoblastic leukemia, according to pre-clinical data published today in the medical journal Pediatric Blood & Cancer.

CPX-351, which is currently undergoing a final-stage study on older patients, was highly efficacious against all xenograft models tested, the company said in a statement.

The company further said the data supported a Phase 1 trial for CPX-351 being conducted on pediatric patients with relapsed acute lymphoblastic leukemia or acute myeloid leukemia.

"CPX-351 has demonstrated broad activity across a variety of cancers and in high-risk patient populations," said Lawrence Mayer, founder of Celator, "and we hope to continue to evaluate its potential in childhood leukemias, where the prognosis is still poor in certain patient subsets."